FTRE Stock Overview
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FTRE from our risk checks.
Fortrea Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$22.42 |
52 Week High | US$41.02 |
52 Week Low | US$18.07 |
Beta | 0 |
11 Month Change | -19.70% |
3 Month Change | -18.62% |
1 Year Change | -15.46% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -25.52% |
Recent News & Updates
Recent updates
Would Fortrea Holdings (NASDAQ:FTRE) Be Better Off With Less Debt?
Aug 16Fortrea Holdings: Still Many Question Marks On This CRO Play
May 12Fortrea: High Risk And Low Upside Potential
Feb 13Fortrea Holdings Inc.'s (NASDAQ:FTRE) Low P/S No Reason For Excitement
Feb 08Fortrea Holdings' (NASDAQ:FTRE) Soft Earnings Are Actually Better Than They Appear
Nov 23Shareholder Returns
FTRE | US Life Sciences | US Market | |
---|---|---|---|
7D | -8.9% | 1.0% | 4.0% |
1Y | -15.5% | 5.6% | 24.9% |
Return vs Industry: FTRE underperformed the US Life Sciences industry which returned 4.2% over the past year.
Return vs Market: FTRE underperformed the US Market which returned 21.7% over the past year.
Price Volatility
FTRE volatility | |
---|---|
FTRE Average Weekly Movement | 9.2% |
Life Sciences Industry Average Movement | 8.2% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: FTRE's share price has been volatile over the past 3 months.
Volatility Over Time: FTRE's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2023 | 16,000 | Tom Pike | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Fortrea Holdings Inc. Fundamentals Summary
FTRE fundamental statistics | |
---|---|
Market cap | US$2.08b |
Earnings (TTM) | -US$215.50m |
Revenue (TTM) | US$3.01b |
0.7x
P/S Ratio-9.3x
P/E RatioIs FTRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FTRE income statement (TTM) | |
---|---|
Revenue | US$3.01b |
Cost of Revenue | US$2.56b |
Gross Profit | US$456.60m |
Other Expenses | US$672.10m |
Earnings | -US$215.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.41 |
Gross Margin | 15.15% |
Net Profit Margin | -7.15% |
Debt/Equity Ratio | 76.9% |
How did FTRE perform over the long term?
See historical performance and comparison